Thirty‐day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life‐threatening direct oral anticoagulant‐related bleeding-Reference-Cited by-同舟云学术

Thirty‐day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life‐threatening direct oral anticoagulant‐related bleeding

Published:2022-03-05 Issue:2 Volume:3 Page:
ISSN:2688-1152
Container-title:Journal of the American College of Emergency Physicians Open
language:en
Short-container-title:JACEP Open

Author:

Cohen Alexander T.¹^ORCID,Lewis Megan²,Connor Augusta²,Connolly Stuart J.³,Yue Patrick⁴,Curnutte John⁴,Alikhan Raza⁵,MacCallum Peter⁶⁷,Tan Joachim⁸,Green Laura⁶⁹¹⁰

Affiliation:

1. Department of Haematological Medicine Guy's and St Thomas’ Hospitals London UK

2. HEOR and Access FIECON Ltd St Albans UK

3. Population Health Research Institute McMaster University Hamilton Ontario Canada

4. Portola Pharmaceuticals, Inc. now Alexion Pharmaceuticals, Inc. South San Francisco California USA

5. University Hospital of Wales, Cardiff and Vale University Health Board Cardiff UK

6. Haemostasis and Transfusion Barts Health NHS Trust London UK

7. Wolfson Institute of Preventive Medicine Queen Mary University of London London UK

8. Population Health Research Institute St George's, University of London London UK

9. Blizard Institute Queen Mary University of London London UK

10. NHS Blood and Transplant London UK

Publisher

Wiley

Subject

Applied Mathematics,General Mathematics

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/emp2.12655

Reference43 articles.

1. National Institute for Health and Care Excellence.Atrial fibrillation: medicines to help reduce your risk of a stroke—what are the options?. Accessed March 29 2021http://guidance.nice.org.uk/CG180/PatientDecisionAid/pdf/English..

2. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials

3. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

4. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials

5. Outcome of intracerebral hemorrhage associated with different oral anticoagulants

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Andexanet alpha versus four-factor prothrombin complex concentrate in DOACs anticoagulation reversal: an updated systematic review and meta-analysis;Critical Care;2024-07-05

2. The 2023 WSES guidelines on the management of trauma in elderly and frail patients;World Journal of Emergency Surgery;2024-05-31

3. Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta‐analysis;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-05

4. Oral Anticoagulants Beyond Warfarin;Annual Review of Pharmacology and Toxicology;2024-01-23

5. Coagulopathy and Prophylaxis of Venous Thromboembolism in Traumatic Brain Injury;Hot Topics in Acute Care Surgery and Trauma;2024